Author Archives: Oxford Biomedica

Novel Dual-Plasmid Transfection System Improves Titer And Product Quality In AAV Manufacturing

Adeno-associated virus (AAV) vectors are a widely-used, versatile, and appealing gene therapy delivery platform because of their high safety profile and ability to target many different cell types and transport healthy gene copies into a patient’s cells. The recent clinical successes of AAV-mediated gene therapies have ignited much interest in solutions for the scalable, good manufacturing practice (GMP) production of AAVs, and high demand for outsourced development and manufacturing capabilities. Yet, significant challenges remain, particularly around product quality, productivity, and…

LentiVector platform: The first and leading commercial lentiviral-based gene delivery system

Oxford Biomedica’s LentiVector platform, which delivered the first FDA and EMA approved CAR-T cell therapy, enables the successful development of breakthrough gene and cell-based medicines. Discover more about the platform and our long and broad clinical and commercial track record, which spans over 25 years. Oxford Biomedica’s LentiVector platform enables the successful development of breakthrough gene and cell-based medicines. We have a long and broad clinical and commercial track record in the gene therapy field spanning over 25 years. Our…